Clinical trials: Meningiomas
Meningioma
Plasma Extracellular Vesicles in Meningioma Patients
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery.
- Trial name
- MOLI (NCT06104930)
- Testing
- Explorative biomarker study
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Heidelberg
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00138216
- Testing
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Where
- 18 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Children's Oncology Group
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Meningioma
ITM11 Expanded Access Program
This Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility.
- Trial name
- NCT07497984
- Testing
- ITM-11
- Sponsor
- ITM Solucin GmbH
Brain Neoplasms
Comparative Study Between Different Approaches to CPA-petroclival Meningiomas
Give an effective treatment for CPA-petroclival meningiomas and can detect the best approach for these tumors. . Improve the outcome of these patients and decease rate of recurrence.
- Trial name
- NCT03462914
- Volunteers
- 80 people
- Sponsor
- Assiut University
Neurofibromatosis Type 2
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.
- Trial name
- POPLAR-NF2 (NCT05130866)
- Testing
- REC-2282
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Brain Cancer, Meningioma
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
This trial is a paucicentric, clinico-biological cohort study with retrospective and prospective enrollment, aiming to identify biomarkers predictive of response to Proton Beam Therapy (PBT) in cancer patients (high grade…
- Conditions
- Brain Cancer, Meningioma, Sarcoma
- Trial name
- PROTONBIOMARKS (NCT04367779)
- Where
- 2 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Leon Berard
Brain and Central Nervous System Tumors, Neuroblastoma
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00503724
- Testing
- enzastaurin hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Brain Meningioma
Sphenoorbital Meningioma Management.
Investigators will discuss the different surgical techniques for removal of spheno_orbital meningiomas with proptosis.investigators also will follow up the patient to know the outcome of removal of these tumours.
- Trial name
- NCT04710485
- Volunteers
- 24 people
- Sponsor
- Assiut University
Brain and Central Nervous System Tumors
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent…
- Trial name
- NCT00006119
- Testing
- hydroxyurea
- Where
- 5 sites in France
- Sponsor
- UNICANCER
Meningioma
Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.
High-risk meningiomas always require postsurgical radiation treatment. Recent evidence has shown that increased radiation therapy dose may be associated with increased intracranial control of disease.
- Trial name
- SPIDER-MEN (NCT06830356)
- Testing
- Dose escalation of radiation therapy, based on somatostatin receptor PET imaging
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Neurofibromatosis 2, Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor.
- Conditions
- Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma
- Trial name
- SEL-TH-1601 (NCT03095248)
- Testing
- Selumetinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Residual, Progressive or Recurrent Grade II or III Meningioma
NEO100 and High-Grade Meningioma
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade…
- Trial name
- NCT05023018
- Testing
- NEO100
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neonc Technologies, Inc.
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain. PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously…
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
- Trial name
- NCT00452868
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)